138 related articles for article (PubMed ID: 28810948)
1. Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices.
Wollmer E; Klein S
J Pharm Pharm Sci; 2017; 20(0):258-269. PubMed ID: 28810948
[TBL] [Abstract][Full Text] [Related]
2. Micellar HPLC-UV method for the simultaneous determination of levodopa, carbidopa and entacapone in pharmaceuticals and human plasma.
Belal F; Ibrahim F; Sheribah ZA; Alaa H
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():36-45. PubMed ID: 29843067
[TBL] [Abstract][Full Text] [Related]
3. Development and application of a high-performance liquid chromatographic method for the determination of in vitro drug release of levodopa, carbidopa, and entacapone from a tablet formulation.
Doshi AS; Upadhyay KJ; Mehta TN; Nanda N
J AOAC Int; 2009; 92(2):394-403. PubMed ID: 19485197
[TBL] [Abstract][Full Text] [Related]
4. A rapid liquid chromatography/tandem mass spectrometry method for simultaneous determination of levodopa, carbidopa, entacapone and their six related compounds in film-coated tablets.
Burmaoğlu RE; Sağlık Aslan S
Rapid Commun Mass Spectrom; 2020 Jun; 34(12):e8782. PubMed ID: 32170976
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous voltammetric determination of levodopa, carbidopa and benserazide in pharmaceuticals using multivariate calibration.
Zapata-Urzúa C; Pérez-Ortiz M; Bravo M; Olivieri AC; Alvarez-Lueje A
Talanta; 2010 Aug; 82(3):962-8. PubMed ID: 20678653
[TBL] [Abstract][Full Text] [Related]
7. Investigation of different spectrophotometric and chemometric methods for determination of entacapone, levodopa and carbidopa in ternary mixture.
Abdel-Ghany MF; Hussein LA; Ayad MF; Youssef MM
Spectrochim Acta A Mol Biomol Spectrosc; 2017 Jan; 171():236-245. PubMed ID: 27541796
[TBL] [Abstract][Full Text] [Related]
8. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
9. Chaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities.
Vemić A; Jančić Stojanović B; Stamenković I; Malenović A
J Pharm Biomed Anal; 2013 Apr; 77():9-15. PubMed ID: 23354116
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of levodopa and carbidopa in levodopa-carbidopa tablets by ATR-FTIR spectrometry.
Khanmohammadi M; Mobedi E; Garmarudi AB; Mobedi H; Kargosha K
Pharm Dev Technol; 2007; 12(6):573-80. PubMed ID: 18161630
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous estimation of levodopa and carbidopa by RP-HPLC using a fluorescence detector: its application to a pharmaceutical dosage form.
Raut PP; Charde SY
Luminescence; 2014 Nov; 29(7):762-71. PubMed ID: 24399763
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous kinetic determination of levodopa and carbidopa by H-point standard addition method.
Safavi A; Tohidi M
J Pharm Biomed Anal; 2007 May; 44(1):313-8. PubMed ID: 17403592
[TBL] [Abstract][Full Text] [Related]
14. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Bugamelli F; Marcheselli C; Barba E; Raggi MA
J Pharm Biomed Anal; 2011 Feb; 54(3):562-7. PubMed ID: 21035976
[TBL] [Abstract][Full Text] [Related]
15. Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Baek JS; Tee JK; Pang YY; Tan EY; Lim KL; Ho HK; Loo SCJ
Neuromolecular Med; 2018 Jun; 20(2):262-270. PubMed ID: 29696585
[TBL] [Abstract][Full Text] [Related]
16. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous chemiluminometric determination of levodopa and benserazide in a multi-pumping flow system with multivariate calibration.
Marques KL; Santos JL; Lopes JA; Lima JL
Anal Sci; 2008 Aug; 24(8):985-91. PubMed ID: 18689938
[TBL] [Abstract][Full Text] [Related]
18. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Delea TE; Thomas SK; Hagiwara M; Mancione L
Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous kinetic-spectrofluorometric determination of levodopa and carbidopa using partial least-squares regression.
Pagani AP; Cabezón MA; Ibáñez GA
Anal Sci; 2009 May; 25(5):633-8. PubMed ID: 19430145
[TBL] [Abstract][Full Text] [Related]
20. Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC; Hauser RA
Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
